Media headlines about Tandem Diabetes Care (NASDAQ:TNDM) have trended somewhat positive this week, according to Accern Sentiment. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Tandem Diabetes Care earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 46.0981899874058 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several equities analysts have recently commented on the company. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $7.50 price objective on the stock in a research report on Thursday, September 28th. Wedbush restated an “outperform” rating and issued a $17.00 price objective (down from $50.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 10th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $15.00 price objective on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Tandem Diabetes Care has a consensus rating of “Hold” and a consensus price target of $12.95.

Shares of Tandem Diabetes Care (NASDAQ:TNDM) traded up $0.23 during trading on Tuesday, hitting $2.97. The stock had a trading volume of 811,800 shares, compared to its average volume of 193,845. Tandem Diabetes Care has a fifty-two week low of $2.15 and a fifty-two week high of $32.50. The company has a current ratio of 1.90, a quick ratio of 0.88 and a debt-to-equity ratio of -2.70.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings data on Thursday, October 26th. The medical device company reported ($3.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($3.74) by $0.65. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. The business had revenue of $27.00 million for the quarter, compared to the consensus estimate of $25.92 million. During the same period in the previous year, the business earned ($0.97) earnings per share. The business’s revenue was up 119.7% on a year-over-year basis. equities research analysts anticipate that Tandem Diabetes Care will post -15.71 EPS for the current fiscal year.

In other news, CEO Kim D. Blickenstaff bought 285,700 shares of Tandem Diabetes Care stock in a transaction dated Friday, October 13th. The shares were purchased at an average cost of $3.50 per share, with a total value of $999,950.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 20.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Tandem Diabetes Care (TNDM) Receiving Somewhat Positive News Coverage, Study Finds” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at

About Tandem Diabetes Care

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Stock Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related stocks with our FREE daily email newsletter.